Mark Bradley

Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom.

BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler.

Ilika Technologies Ltd is a privately held company which was spun out of the University of Southampton in May 2004. Ilika quickly established a reputation for innovation, revenue generation and profitability in the high growth industry of materials development. As a result, the company has attracted investment from blue chip investors who have provided the resources necessary to support the rapid growth of the company. Although many industries are addressable through the company's high throughput technology, Ilika has chosen to focus upon the energy, electronics and biomedical sectors. The company's technology and discovered materials are protected through worldwide patent applications. Ilika engages with customers through research collaborations and through the licensing of materials which Ilika has developed for different applications.